View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Trastuzumab Deruxtecan 5.4 / Pertuzumab 420, Breast Cancer, Cycle 2+
Protocol-ID: 3002 V1.0 (Mini), TRASDE5.4/PERT420, Breast Ca, C2+Indication(s)
- Breast Cancer; ICD-10 C50.-
HER2+
Links
- Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. [ASCO Abstracts doi]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 21.09.2025